EU approves AstraZeneca/Pozen's Vimovo
This article was originally published in Scrip
AstraZeneca/Pozen's arthritis drug Vimovo (naproxen and esomeprazole magnesium) now has regulatory approval in the EU, AstraZeneca has confirmed.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.